Evidence map›Paper›PMID 28594322›Full record

ArticleeLife2017

Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma.

Giulia Fianco, Maria Patrizia Mongiardi, Andrea Levi, Teresa De Luca, Marianna Desideri, Daniela Trisciuoglio, Donatella Del Bufalo, Irene Cinà, Anna Di Benedetto, Marcella Mottolese and 4 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cell death in glioblastoma and the central nervous system.Cellular oncology (Dordrecht, Netherlands) · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Giulia FiancoDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Maria Patrizia MongiardiInstitute of Cell Biology and Neurobiology, Consiglio Nazionale delle Ricerche (CNR), Rome, Italy.
Andrea LeviInstitute of Cell Biology and Neurobiology, Consiglio Nazionale delle Ricerche (CNR), Rome, Italy.
Teresa De LucaPreclinical Models and New Therapeutic Agents Unit, Research, Advanced Diagnostics and Technological Innovation Department, Regina Elena National Cancer Institute, Rome, Italy.
Marianna DesideriPreclinical Models and New Therapeutic Agents Unit, Research, Advanced Diagnostics and Technological Innovation Department, Regina Elena National Cancer Institute, Rome, Italy.
Daniela TrisciuoglioPreclinical Models and New Therapeutic Agents Unit, Research, Advanced Diagnostics and Technological Innovation Department, Regina Elena National Cancer Institute, Rome, Italy.
Donatella Del BufaloPreclinical Models and New Therapeutic Agents Unit, Research, Advanced Diagnostics and Technological Innovation Department, Regina Elena National Cancer Institute, Rome, Italy.
Irene CinàLaboratory of Cell Signaling, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia, Rome, Italy.
Anna Di BenedettoPathology Department, Regina Elena National Cancer Institute, Rome, Italy.
Marcella MottolesePathology Department, Regina Elena National Cancer Institute, Rome, Italy.
Antonietta GentileMultiple Sclerosis Clinical and Research Center, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Diego CentonzeMultiple Sclerosis Clinical and Research Center, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Fabrizio FerrèDepartment of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy.ORCID 0000-0003-2768-5305
Daniela BarilàDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.ORCID 0000-0002-6192-1562
University of Rome Tor Vergata · ITNational Research Council · ITFondazione Santa Lucia · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Caspase-8 is a key player in extrinsic apoptosis and its activity is often downregulated in cancer. However, human Caspase-8 expression is retained in some tumors, including glioblastoma (GBM), suggesting that it may support cancer growth in these contexts. GBM, the most aggressive of the gliomas, is characterized by extensive angiogenesis and by an inflammatory microenvironment that support its development and resistance to therapies. We have recently shown that Caspase-8 sustains neoplastic transformation in vitro in human GBM cell lines. Here, we demonstrate that Caspase-8, through activation of NF-kB, enhances the expression and secretion of VEGF, IL-6, IL-8, IL-1beta and MCP-1, leading to neovascularization and increased resistance to Temozolomide. Importantly, the bioinformatics analysis of microarray gene expression data derived from a set of high-grade human gliomas, shows that high Caspase-8 expression levels correlate with a worse prognosis.

Indexed as

Drug Resistance, NeoplasmCaspase 8CytokinesGene Expression ProfilingGlioblastomaHumansMicroarray AnalysisNeovascularization, PathologicNF-kappa BPrognosisVascular Endothelial Growth Factor ACASP8 protein, humanCaspase 8CytokinesNF-kappa BVascular Endothelial Growth Factor Aangiogenesiscancercancer biologycell biologycell deathcell proliferationhumanmousesignal transduction

Identifiers

PMID28594322
PMCPMC5464770
OpenAlexW2624114007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.